Search for: [Abstract = "In the present time, chronic respiratory diseases constitute a serious and challenging problem facing modern science and healthcare. 650 million people suffer from the chronic obstructive pulmonary disease \(COPD\) worldwide and over 330 million contend with asthma. In the epidemic of SARS\-COV\-2 causing COVID\-19, where COPD was a state of increased risk of severe course, the problem of effective treatment of these diseases appears to be even more alarming. The currently available therapeutic strategies for asthma and COPD have anti\-inflammatory and bronchodilatory effects, which, however, do not cover all the most important pathological processes in the course of both diseases. Therefore, there is an urgent need to develop possible, comprehensive solutions. The multifactorial nature of diseases provides the logical foundation for the development of an innovative drug design strategy based on multi\-target\-directed ligands \(MTDL\), which gives the potential to broaden the spectrum of therapy and achieve a cumulatively stronger therapeutic effect. A possible solution could be rationally designed MTDLs combining PDE4B and PDE8A inhibition with TRPA1 ion channel antagonism. PDE4B, PDE8A, and TRPA1 are expressed simultaneously in many cells relevant to the pathogenesis of chronic respiratory diseases. Their complementary and synergistic anti\-inflammatory and bronchodilatory effects sug"]
